BRCA2 and ovarian carcinoma: HBOC is associated with pathogenic variants (PVs) in BRCA1 or BRCA2, where BRCA1 PVs are associated with a 39–63% lifetime risk of ovarian cancer and BRCA2 PVs are associated with a 15–27% risk.